Triamcinolone Acetonide alone

PreclinicalSmall molecule

Triamcinolone Acetonide alone is one of 6 small molecule programs targeting Retinal Vein Occlusion. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal Vein OcclusionActive, not recruiting

Retinal Vein OcclusionPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Retinal Vein Occlusion

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

6 2

Niacor

Celestone

Anti-VEGF Drug

FFirst Affiliated Hospital of Chongqing Medical University

Phase 3

1 5

Avastin

Roche

Preclinical

2 6

Triamcinolone Acetonide alone

AAl-Azhar University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinal Vein Occlusion1 trial

Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions

Completed·—·N/A·NCT05385562·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Triamcinolone Acetonide alone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triamcinolone Acetonide alone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triamcinolone Acetonide alone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Al-Azhar University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAl-Azhar University

Triamcinolone Acetonide alone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Retinal Vein Occlusion1 trial

References

Drug Info

Quick Facts

Related News